Sanofi and Regeneron Provide Update on U.S. Kevzara Phase 2/3 Adaptive-Designed Trial in Hospitalized COVID-19 Patients

Paris and Tarrytown, N.Y. April 27, 2020– Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials